{"groups":[{"description":"Participants received bortezomib 1.3 mg/m² administered intravenously (IV) or subcutaneously (SC) on Days 1, 4, 8, and 11 of a 21-day cycle plus dexamethasone (DEX) 20 mg administered on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.","id":"FG000","title":"Bortezomib + DEX"},{"description":"Participants received 20 mg/m² carfilzomib administered by IV infusion on Days 1 and 2 of Cycle 1, followed by 56 mg/m² on Days 8, 9, 15, and 16 of Cycle 1 and for each 28-day cycle thereafter. Additionally, participants received 20 mg dexamethasone on Days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28 day cycle.","id":"FG001","title":"Carfilzomib + DEX"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"208"},{"groupId":"FG001","numSubjects":"183"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"94"},{"groupId":"FG001","numSubjects":"96"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"55"},{"groupId":"FG001","numSubjects":"71"}],"type":"Patient Request"},{"reasons":[{"groupId":"FG000","numSubjects":"40"},{"groupId":"FG001","numSubjects":"32"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"11"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"18"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"4"}],"type":"Protocol Non-compliance"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"1"}],"type":"Randomized but Not Dosed"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"465"},{"groupId":"FG001","numSubjects":"464"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"456"},{"groupId":"FG001","numSubjects":"463"}],"type":"Received Treatment"},{"achievements":[{"comment":"Indicates participants still receiving treatment","groupId":"FG000","numSubjects":"27"},{"comment":"Indicates participants still receiving treatment","groupId":"FG001","numSubjects":"48"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"438"},{"groupId":"FG001","numSubjects":"416"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Randomization was stratified by previous proteasome inhibitor therapy (yes vs no), previous lines of treatment (1 vs 2 or 3), International Staging System stage (I vs II-III), and planned route of bortezomib administration (intravenous vs subcutaneous) if randomly assigned to the bortezomib group.","recruitmentDetails":"Adults with relapsed multiple myeloma were enrolled between 20 June 2012 and 30 June 2014 at 198 centers in 27 countries in Europe, North America, South America, and the Asia-Pacific region.\n\nResults are reported as of the data cut-off date of 03 January 2017, the pre-specified 2nd interim analysis of the secondary endpoint of overall survival."}